The effect of gum consumption on anthropometric characteristics and cardiac disorders: A systematic review and meta-analysis of randomized controlled trials.

OBJECTIVE: No systematic review and (or) meta-analysis has been conducted so far to study the effect of gum consumption on anthropometric indices and blood pressure. Thus, our objective was to conduct a systematic review and meta-analysis of the randomized controlled trials investigating the effect of gum consumption on anthropometric indices and cardiac disorders. METHODS: The literature search was implemented in the Scopus, Web of Science, PubMed/Medline and Google Scholar databases to discover trials that investigated the impact of gum on obesity indices and cardiac disorders up to April 2019. In order to calculate effect sizes, the random-effects model (using the DerSimonian-Laird method) was applied. RESULTS: Finally, 21 articles were included in this meta-analysis. Combined results indicated that body weight (WMD: -0.60 kg, 95 % CI: -1.13, -0.07, P = 0.026, I2 = 89 %), and WC (WMD: -1.36 cm, 95 % CI: -2.50, -0.22, P = 0.019, I2 = 96 %) changed significantly following gum consumption. Subgroup analyses showed that a gum dosage ≤15 g/day (WMD: -1.23 kg/m2, 95 % CI: -2.03 to -0.43, I2 = 99 %) significantly decreased BMI. Moreover, gum consumption had significant effects on cardiac disorders. CONCLUSION: In conclusion, gum supplementation may be an adjuvant for controlling obesity and can possess potential benefits in the management of cardiac disorders.

The effect of green tea supplementation on obesity: A systematic review and dose-response meta-analysis of randomized controlled trials.

The effects of green tea (GT) in obese subjects have been evaluated in different studies, but no consensus has been obtained due to the heterogeneity of the results. The dosage, the type of extract, and the duration of the intervention are the main contributors to the heterogeneity of the results. Therefore, the present systematic review and meta-analysis aimed to evaluate the efficacy and dose-response relationship of GT. Several databases were searched from inception to September 2019 to identify clinical trials that examined the influence of GT supplements on obesity indices in humans. Combined results using the random-effects model indicated that body weight (WMD: -1.78 kg, 95% CI: -2.80, -0.75, p = .001) and body mass index (BMI) (WMD: -0.65 kg/m2 , 95% CI: -1.04, -0.25, p = .001) did change significantly following GT administration. The reduction in waist circumference (WC) after GT consumption was significant in subjects in trials employing GT ≥800 mg/day (WMD: -2.06 cm) and with a treatment duration <12 weeks (WMD: -2.39 cm). Following the dose-response evaluation, GT intake did alter body weight, with a more important reduction when the GT dosage was <500 mg/day and the treatment duration was of 12 weeks. The results of present meta-analysis study support the use of GT for the improvement of obesity indices. Thus, we suggest that the use of GT can be combined with a balanced and healthy diet and regular physical exercise in the management of obese patients.

The influence of green coffee bean extract supplementation on blood glucose levels: A systematic review and dose-response meta-analysis of randomized controlled trials.

Studies regarding the influence of green coffee extract (GCE) on blood glucose levels are conflicting. Thus, we sought to conduct a meta-analysis and systematic review of all available randomized controlled trials (RCTs) to quantify the effects of GCE and CGA intervention on blood glucose and insulin levels. We performed systematic online searches in Scopus, Web of science, and PubMed databases, from inception to July 2019. Data were combined analyzed using a random effects model (Der Simonian-Laird method) and reported as weighted mean differences (WMD). Ten trials reported the influences of GCE on FBS and insulin and were subsequently entered into the meta-analysis. Combined results highlighted that FBS was significantly altered after GCE consumption (WMD: -1.791 mg/dl, 95% CI -3.404, -0.177), with no significant heterogeneity among the studies (I2 = 35.0%, p = .128). However, overall results demonstrated that GCE administration did not result in any significant alteration in insulin levels (WMD: -0.925 µU/ml, 95% CI:-1.915, 0.064), with significant heterogeneity found across studies (I2 = 87.9%). In sub-group analysis, insulin levels were significantly reduced when GCE was supplemented in dosages of ≥400 mg/day (WMD:-1.942 mg/dl, 95% CI:-1.184, -0.975; I2 = 0.0%). The results of present study support the use of GCE for the enhancement of blood glucose, while subgroup analysis highlighted significant improvements in insulin levels when GCE is supplemented in doses ≥400 mg/day.